Alembic Pharma Peer Comparison

NSE: APLLTD | BSE: 533573

₹861.50

₹7.15 (0.84%)

As on 29-Sep-2026IST

Market cap

₹16,905 Cr

Revenue (TTM)

₹7,784 Cr

P/E Ratio

24.4

P/B Ratio

2.9

Div. Yield

1.4 %

Edit

	Alembic Pharma	Acutaas Chemicals	Cohance Lifesciences	Granules India	Jubilant Pharmova	Onesource Specialty Pharma	Piramal Pharma	Rubicon Research	Syngene Intl	Wockhardt
Market cap (₹ Cr)	16,905	27,040	17,475	23,669	16,720	18,169	27,932	26,719	14,863	35,717
Revenue (₹ Cr)	7,784	1,462	2,142	5,632	8,608	1,543	9,205	1,936	3,600	3,564
Net Profit (₹ Cr)	688.47	387.35	58.53	662.35	351.60	-48.62	-371.81	288.22	221.00	414.00
Net Margin (%)	8.77	26.01	2.69	11.75	4.05	-3.12	-3.93	14.79	6.01	11.23
RoE (%)	14.02	25.18	3.29	14.34	5.68	-0.61	-3.85	29.77	5.62	8.38
Price to Earnings	24.38	70.01	164.50	35.74	47.49	--	--	92.70	67.25	87.33
Price-To-Book	2.89	15.67	4.54	4.83	2.34	3.11	3.49	19.90	3.14	7.09

Income Statement (₹ Cr)

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	7,783.95	3,564.00	9,205.28	1,935.80	1,461.80
Total Income	7,846.79	3,686.00	9,449.59	1,948.58	1,489.25
Total Expenditure	6,614.98	2,792.00	8,195.15	1,485.56	919.25
EBITDA	1,168.97	772.00	1,010.13	450.24	542.56
Depreciation	342.49	226.00	857.51	50.83	37.68
EBIT	826.48	546.00	152.62	399.41	504.88
Interest	97.71	217.00	342.73	40.84	3.77
Other Income	62.84	122.00	244.31	12.78	27.45
Exceptional Items	-66.99	12.00	-216.88	0.00	0.00
Profit before Tax	724.62	463.00	-162.68	371.35	528.56
Provision for Tax	36.15	49.00	209.13	83.14	141.21
Profit after Tax	688.47	414.00	-371.81	288.22	387.35

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	5,674.81	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	3.90	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	499.77	1,712.00	5,044.14	202.03	42.40
Current Liabilities	2,593.84	1,622.00	4,758.28	835.87	230.82
Total Liabilities	8,855.62	8,578.00	17,723.32	2,326.71	1,983.96

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	4,174.56	5,343.00	10,211.52	519.60	1,026.85
Current Assets	4,542.60	2,606.00	7,191.66	1,681.81	881.27
Total Assets	8,855.62	8,578.00	17,723.32	2,326.71	1,983.96
Total Debt*	1,360.85	2,125.00	5,495.48	259.37	26.49
Net Current Assets	1,948.76	984.00	2,433.38	845.94	650.46
Contingent Liabilities	160.39	768.26	95.72	19.09	17.25

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	782.73	390.00	1,652.60	205.05	292.17
Cash Flow from Investing Activities	-506.06	-241.00	-826.03	-409.72	-265.94
Cash from Financing Activities	-163.78	-54.00	-38.98	283.07	4.10
Net Cash Inflow / Outflow	112.89	95.00	787.59	78.39	30.33

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	11.74	6.79	1.24	29.22	32.42
ROE (%)	14.02	8.38	-3.85	29.77	25.18
ROA (%)	8.33	4.94	-2.21	24.77	21.93
EBIT Margin (%)	10.62	15.32	1.66	20.63	34.54
Net Margin (%)	8.77	11.23	-3.93	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	14.12	18.37	0.78	46.65	40.90
EBIT Growth (%)	7.41	252.26	-70.53	62.13	124.50
Net Profit Growth (%)	14.55	377.85	-1,383.43	89.49	104.15
EPS Growth (%)	30.14	1,001.33	-484.84	78.60	42.32
Book Value Growth (%)	9.32	13.47	0.33	144.31	26.03

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	21.94	89.63	-89.26	91.28	70.01
Price / Book Value	2.89	7.09	3.49	19.90	15.67
Dividend Yield (%)	1.40	0.00	0.00	0.09	0.08
EV/EBITDA	15.45	48.16	31.75	59.15	49.47
Market Cap (₹ Cr)	13,008.55	19,071.62	18,108.89	12,753.19	20,944.75

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.02	0.31	0.53	0.11	0.02
Short term debt to equity ratio	0.21	0.09	0.09	0.05	0.02
Current Ratio	1.75	1.61	1.51	2.01	3.82
Quick Ratio	0.78	1.06	0.87	1.14	2.82
Interest Coverage	8.42	3.13	0.53	10.09	141.16

	Alembic Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	18.84	16.50	23.44	26.28	24.80
Asset Turnover	0.94	0.43	0.55	1.66	0.83
Receivable days	36.70	58.75	78.20	40.13	88.98
Inventory Days	61.45	75.82	93.30	60.29	56.04
Payable days	157.72	186.21	226.14	232.47	99.95
Cash Conversion Cycle	-59.57	-51.64	-54.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.